Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Elanco Animal Health Incorporated (NYSE: ELAN) SEC filings page on Stock Titan provides organized access to the company’s U.S. regulatory disclosures. As an Indiana-incorporated public company in the pharmaceutical preparation manufacturing industry, Elanco files reports with the Securities and Exchange Commission under Commission File Number 001-38661.
Through this page, readers can review current and historical Forms 8-K and, when available, annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy materials. Elanco’s recent Form 8-K filings illustrate the range of topics covered in its SEC disclosures, including quarterly financial results and guidance, restructuring plans and workforce changes, amendments to credit agreements and receivables facilities, and participation in major investor events such as its Investor Day and healthcare conferences.
These filings provide detail on Elanco’s financial condition, capital structure and risk factors, as well as material contracts and strategic initiatives. For example, recent 8-Ks describe the Elanco Ascend restructuring program, expected cost savings, facility changes, and refinancing of term loan facilities, along with updates on leverage targets and cash flow expectations. Other filings outline amendments to securitization and credit agreements that affect the company’s direct financial obligations.
Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the significance of each filing. Investors can use the ELAN filings page to monitor new 8-Ks, as well as future 10-K and 10-Q reports, and to track how management’s strategic, financial and operational decisions are reflected in official SEC documents.
Elanco Animal Health’s president and CEO Jeffrey N. Simmons reported an acquisition of derivative equity compensation. On January 23, 2026, he received 113.4934 deferred stock units at a reference price of
Each deferred stock unit gives the right to receive either one share of Elanco common stock or the cash equivalent. These units will settle in cash or shares after his employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health executive Rajeev A. Modi reported a routine equity compensation transaction. On 01/23/2026, he was awarded 57.9762 deferred stock units at a reference price of
The deferred stock units each represent the right to receive either one share of Elanco common stock or the cash equivalent. They will settle in cash or shares after termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health executive Robert M. VanHimbergen, EVP and CFO, reported an acquisition of derivative securities. On January 23, 2026, he acquired 7.8029 deferred stock units at a reference price of
Following this transaction, he beneficially owned 15.915 deferred stock units directly. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent and will settle in cash or shares after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Dimensional Fund Advisors LP filed a Schedule 13G reporting a passive ownership stake in Elanco Animal Health Inc. common stock. As of 12/31/2025, Dimensional is deemed to beneficially own 25,082,545 shares, representing 5.0% of Elanco’s common stock. The firm has sole voting power over 24,595,193 shares and sole dispositive power over 25,082,545 shares.
The shares are actually owned by various funds and accounts advised or sub-advised by Dimensional. Dimensional states that it may be deemed a beneficial owner only for Section 13(d) purposes and expressly disclaims beneficial ownership. The position is certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of Elanco.
Elanco Animal Health executive Rajeev A. Modi reported an award of deferred stock units. On 01/09/2026, he acquired 60.2735 deferred stock units at a value of $23.47 per unit, classified as a derivative security and held directly.
Following this transaction, Modi beneficially owned a total of 7,480.3494 deferred stock units. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and these units settle in cash or shares after termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health executive Robert M. VanHimbergen, EVP and CFO, reported a small compensation-related equity transaction. On 01/09/2026 he acquired 8.1121 deferred stock units at a reference price of
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and the units settle in cash or shares following termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan. After this transaction, he beneficially owns 8.1121 deferred stock units directly.
Elanco Animal Health Inc. CEO Jeffrey N. Simmons, who also serves as president and director, reported an acquisition of deferred stock units under a company plan. On January 9, 2026, he was credited with 117.9906 deferred stock units at a reference price of $23.47 per unit, bringing his total holdings to 18,845.5217 deferred stock units.
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. These units are designed to settle in cash or shares after employment ends or in a specified future year, in line with the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health Incorporated filed a report stating that on January 13, 2026, it will present at the 44th Annual J.P. Morgan Healthcare Conference. The company has prepared an investor presentation for this event, which is included as Exhibit 99.1. This presentation is being made available as supplemental information for investors and analysts.
The disclosure is furnished under a provision that means it is not considered “filed” for liability purposes under the Securities Exchange Act and will only be incorporated into other documents if expressly stated. No financial results, transactions, or strategic changes are described in this report beyond the announcement of the conference presentation.
Elanco Animal Health director defers fees into stock units. Director Kapila K. Anand converted a portion of her cash director fees into deferred stock units under Elanco's Directors' Deferral Plan on December 31, 2025. She received 381.1312 Deferred Stock Units, each economically equivalent to one share of Elanco common stock, based on the closing share price of $22.63 on the grant date. Following this transaction, she held a total of 8,894.7414 deferred stock units, which will be settled in Elanco common stock when she separates from the Board of Directors.
Elanco Animal Health Inc. insider Jeffrey N. Simmons, the company’s President, CEO and Director, reported an acquisition of derivative securities in the form of deferred stock units on 12/26/2025. The filing shows he acquired 122.5327 deferred stock units tied to Elanco common stock at a derivative price of
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. These units are scheduled to settle in cash or shares of Elanco common stock after termination of employment or during a specified future year under the company’s Executive Deferral and Stock Match Plan.